Detalhe da pesquisa
1.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
Hepatology
; 79(3): 674-689, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37732990
2.
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
Am J Gastroenterol
; 116(12): 2399-2409, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382947
3.
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
J Hepatol
; 72(5): 816-827, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31887369
4.
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
J Hepatol
; 72(5): 885-895, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870950
5.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med
; 376(22): 2134-2146, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28564569
6.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
N Engl J Med
; 370(16): 1483-93, 2014 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24725238
7.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology
; 61(4): 1127-35, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25614962
8.
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
J Hepatol
; 63(1): 30-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25703086
9.
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
Hepatol Commun
; 8(2)2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38285756
10.
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol
; 7(7): 603-616, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325622
11.
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Clin Gastroenterol Hepatol
; 9(8): 670-678.e3, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21642014
12.
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
J Crohns Colitis
; 12(9): 1021-1029, 2018 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29767728
13.
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease.
J Crohns Colitis
; 12(9): 1014-1020, 2018 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29846530
14.
Role of growth factors in oesophageal mucosal healing: A work in progress.
J Gastroenterol Hepatol
; 13(S3): S156-S160, 1998 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28976681